Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease

New England Journal of Medicine

Volumn 328, Issue 3, 1993, Pages 176-183

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; LEVODOPA; SELEGILINE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HALLUCINATION; HAMILTON SCALE; HEART ARRHYTHMIA; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SURVIVAL RATE;

ACTIVITIES OF DAILY LIVING; ARRHYTHMIA; COMPARATIVE STUDY; FOLLOW-UP STUDIES; HUMAN; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; REGRESSION ANALYSIS; SELEGILINE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VITAMIN E;

EID: 0027530638     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199301213280305     Document Type: Article

References (34)

1. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989; 46:1052-1060
2. Riederer P, Youdim MB Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 1986; 46:1359-1365
3. Chrisp P, Mammen GJ, Sorkin EM Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1991; 1:228-248
4. Willson RL. Free radical protection: why vitamin E, not vitamin C, beta-carotene or glutathione? In: Biology of vitamin E: Ciba Foundation Symposium 101. London: Pitman, 1983:19-44.
5. Halliwell B, Gutteridge JMC Oxygen radicals and the nervous system. Trends Neurosci 1985; 8:22-26
6. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321:1364-1371
7. Stampfer MJ, Buring JE, Willett W, Rosner B, Eberlein K, Hennekens CH The 2 × 2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians. Stat Med 1985; 4:111-116
8. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworths, 1989:285-309.
9. Hamilton M A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
10. Peto R, Pike MC, Armitage P, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34:585-612
11. Cox DR, Oakes D. Analysis of survival data. Vol. 21 of Monographs on statistics and applied probability. London: Chapman and Hall, 1984.
12. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
13. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford, England: Blackwell, 1987:205.
14. Peto R, Pike MC, Armitage P, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35:1-39
15. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34:187-220
16. Dixon WJ, ed. BMDP statistical software manual. Vol. 2. Berkeley: University of California Press, 1990:795.
17. Oakes D, Parkinson Study Group. Progression of early Parkinson's disease until levodopa therapy is required. Neurology 1990; 40: Suppl 1: 370-370 abstract.
18. Birkmayer W, Knoll J, Riederer P, Youdim MB (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry 1983; 19:170-176
19. Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 1985; 64:113-127
20. Rinne JO, Roytta M, Paljarvi L, Rummukainen J, Rinne UK Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology 1991; 41:859-861
21. Eisler T, Teravainen H, Nelson R, Deprenyl in Parkinson disease. Neurology 1981; 31:19-23
22. Csanda E, Tarczy M Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neurol Scand Suppl 1983; 95:117-22
23. Golbe LI Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology 1989; 39:1109-1111
24. Fahn S The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high-dosage antioxidants in an attempt to slow the progression of the illness. Ann N Y Acad Sci 1989; 570:186-196
25. Tetrud JW, Langston JW The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245:519-522
26. Teravainen H Selegiline in Parkinson's disease. Acta Neurol Scand 1990; 81:333-336
27. Allain H, Cougnard J, Neukirch H-C, FSMT members. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT). Acta Neurol Scand Suppl 1991; 136:73-78
28. Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992; 42:339-343
29. Stern GM, Lees AJ, Hardie R, Sandler M Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease. Mod Probl Pharmacopsychiatry 1983; 19:215-219
30. Parkes JD, Tarsy D, Marsden CD, Amphetamines in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1975; 38:232-237
31. Parkinson Study Group. Assessment of the short-term tolerability of lazabemide (Ro 19-6327) in untreated Parkinson's disease. Mov Disord 1992; 7:293-294 abstract.
32. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW Distinct monoamine oxidase A and B populations in primate brain. Science 1985; 230:181-183
33. Konradi C, Kornhuber J, Froelich L, Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 1989; 33:383-400
34. Oakes D, McDermott M, Eberly S, Investigator effects in a multicenter trial for Parkinson's disease. Control Clin Trials 1990; 11:284-284 abstract.